Exelixis Inc

EXEL

$23.40

+27.31% (1 year change)

Avg closing price

Price range

Market Cap

$7.39 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

$270 Million

Total revenue in the last quarter.

Net Income

$28.4 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$0.35

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

66.08x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$24.3 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

0

The number of full time employees.

Revenue & Earnings

Balance Sheet

News

Exelixis to Webcast Virtual Fireside Chat as Part of the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021

Exelixis to Webcast Virtual Fireside Chat as Part of the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer will participate in a fireside ...

Business Wire Business Wire, 2 months ago
Exelixis : Highlights Positive Results for CABOMETYX® (cabozantinib) in Patients with Metastatic Papillary Renal Cell Carcinoma in SWOG S1500/PAPMET Study at ASCO GU | MarketScreener

Exelixis : Highlights Positive Results for CABOMETYX® (cabozantinib) in Patients with Metastatic Papillary Renal Cell Carcinoma in SWOG S1500/PAPMET Study at ASCO GU | MarketScreener

– Results of phase 2 trial show CABOMETYX significantly improved progression-free survival versus current guideline-preferred therapy – – Data to be presented during the 2021… | February 13, 2021

MarketScreener MarketScreener, 2 months ago
Exelixis Announces Final Phase 1 Results from Clinical Trial Sponsored by the National Cancer Institute at ASCO GU for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Patients with Refractory Metastatic Genitourinary Tumors

Exelixis Announces Final Phase 1 Results from Clinical Trial Sponsored by the National Cancer Institute at ASCO GU for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Patients with Refractory Metastatic Genitourinary Tumors

Exelixis, Inc. (NASDAQ: EXEL) today announced positive final data for a phase 1 trial sponsored and conducted by the U.S. National Cancer Institute (N

Business Wire Business Wire, 2 months ago